首页> 外文OA文献 >Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

【2h】

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

机译：分子成像作为调查高级HER2阳性乳腺癌的异质性的工具，并在曲妥珠单抗（T-DM1）下预测患者结果（T-DM1）：Zephir试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
G. Gebhart; L.E. Lamberts; Z. Wimana; C. Garcia; P. Emonts; L. Ameye; S. Stroobants; M. Huizing; P. Aftimos; J. Tol; W.J.G. Oyen; D.J. Vugts; O.S. Hoekstra; C.P. Schröder; C.W. Menke-van der Houven van Oordt; T. Guiot; A.H. Brouwers; A. Awada; E.G.E. de Vries; P. Flamen;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial [J] . Gebhart G., Lamberts L. E., Wimana Z., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第4期

机译：分子成像作为研究晚期HER2阳性乳腺癌异质性并预测曲妥珠单抗坦坦（T-DM1）患者预后的工具：ZEPHIR试验
2. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer [J] . Lu Dan, Li Chunze, Riggs Matthew, Cancer chemotherapy and pharmacology. . 2019,第1期

机译：Trastuzumab Emtansine（T-DM1）的药代动力学作为单一的药剂，或者与患有复发或局部晚期转移性乳腺癌的HER2阳性乳腺癌患者中的Pertuzumab
3. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study [J] . Kojima Yasuyuki, Yoshie Reiko, Kawamoto Hisanori, Oncology: International Journal of Cancer Research and Treatment . 2019,第6期

机译：Trastuzumab Emtansine（T-DM1）加S-1患者曲妥珠单抗预处理HER2阳性晚期或转移性乳腺癌：IB研究
4. Molecular Signatures of Estrogen Receptor-Associated Genes in Breast Cancer Predict Clinical Outcome [C] . James L. Wittliff, TYaci L. Kruer, Sarah A. Andres, International Symposium on Hormonal Carcinogenesis . 2008

机译：乳腺癌中雌激素受体相关基因的分子鉴定预测临床结果
5. Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1) [D] . Al-saden, Noor. 2019

机译：宠物成像探针的发展，以预测乳腺癌对曲妥珠单抗的响应（T-DM1）
6. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab [O] . Laura L. Michel, Andreas D. Hartkopf, Peter A. Fasching, 2020

机译：在先前用Pertuzumab治疗后用曲妥珠单抗（T-DM1）治疗先进的Her2阳性乳腺癌患者的无进展生存和整体存活
7. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1 [O] . Filippo Montemurro, Paul Ellis, Antonio Anton, 2019

机译：Trastuzumab Emtansine（T-DM1）在Her2阳性晚期乳腺癌患者中的安全性：Kamilla研究队列的主要结果1

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

著录项

引文网络

相似文献

相关主题

期刊订阅